With the coronavirus showing no signs of slowing, the world is in desperate need for a treatment — and fast. Thankfully, we may be nearing potential solutions, which could drive these three stocks even higher.
One, shares of OPKO Health (OPK) are picking up a good deal of momentum, as markets wait for news on its Phase 2 data on rayaldee, a potential treatment for mild to moderate COVID-19. The company expects to report its data before year end. “The trial will be conducted at multiple COVID-19 outpatient clinics in the U.S. The initial sites are located primarily in South Florida, the Central Gulf coast, the Midwest and the Southwest. The first subjects are expected to be enrolled within the next few weeks,” according to the company’s latest press release.
Two, while the US FDA halted Inovio Pharmaceuticals’ (INO) Phase 2/3 trial, it had nothing to do with the vaccine. It had to do with the delivery system INO is using, according to reports. In our opinion, the clinical hold could be lifted by the end of October, clearing the way for potentially explosive upside in INO.
And three, Pfizer (PFE) CEO Albert Bourla just said there’s a “good chance” the company will know if its vaccine works by the end of October 2020. The CEO told Face the Nation, “We started already manufacturing and we have already manufactured hundreds of thousands of doses, so just in case we have a good study readout, conclusive and FDA, plus the advisory committee feels comfortable that we will be ready.”
